• Atriva Therapeutics and Canadian Biocure Technology, Inc. entered into an exclusiveletter agreement for a reverse takeover transaction.• Upon successful completion of the transaction, the…
Our non-clinical activities yielded promising results in influenza and SARS-CoV-2 cell line studies and animal studies. We’re now planning the Phase 2 “SURVIVE” trial to…
Our non-clinical activities yielded promising results in influenza and COVID-19 cell line studies and animal studies. We’re now planning the Phase 2 “SURVIVE” trial to…
Tübingen, Frankfurt am Main, Martinsried, Germany, November 9, 2022 – Today, Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced…
The Innovation and Start-Up Center for Biotechnology (IZB), one of the leading biotechnology centers in Europe with over 50 biotech start-ups based there, today announced that the Tübingen biotech company Atriva Therapeutics GmbH is moving into the IZB.
Today, Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced its participation in upcoming industry and investor conferences.
Atriva Therapeutics announces Topline Results from the
Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib)
in patients hospitalized with COVID-19
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics to take part in upcoming scientific and industry conferences
Atriva Therapeutics to take part in upcoming scientific and industry conferences